Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, ...

Shares of Keros Therapeutics (NASDAQ:KROS) added ~22% in the premarket on Thursday after the biotech commenced a review ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price ...

$KROS insiders have traded $KROS stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales. Here’s a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...